Dyadic Logs $8.6M Cash, OEM Deal and AlbuFree™ DX Launch
Dyadic closed 2025 with $8.6 million in cash and investment-grade securities and secured an OEM distribution deal with IBT Bioservices for recombinant DNase I and transferrin. The company launched AlbuFree™ DX with Proliant, expanded Fermbox Bio collaboration, signed a BRIG Bio alpha-lactalbumin agreement and anticipates non-animal chymosin commercialization in 2026.
1. 2025 Financial Position
Dyadic ended 2025 with $8.6 million in cash, cash equivalents, restricted cash and investment-grade securities. This liquidity provides runway for continued product development and supports upcoming commercialization initiatives.
2. Commercial Partnerships and Launches
In early 2026 Dyadic’s platform powered the commercial launch of AlbuFree™ DX recombinant human albumin with Proliant, entitling Dyadic to profit share. The company also sealed an OEM distribution agreement with IBT Bioservices for recombinant DNase I and transferrin and expanded its Fermbox Bio collaboration, while signing a development and commercialization deal with BRIG Bio for alpha-lactalbumin and prepping non-animal chymosin launch in 2026.
3. Pipeline Expansion and Grant-Funded Programs
Beyond core partnerships, Dyadic is advancing recombinant transferrin, growth factors and a suite of nucleic acid enzymes. Grant-supported work under Gates Foundation and CEPI programs is progressing on low-cost monoclonal antibodies and vaccine antigens using the C1 platform, positioning the company for future non-dilutive funding and potential pharmaceutical applications.